Low-dose chemotherapy and rituximab for post-transplant lymphoproliferative disease (PTLD): A Children's Oncology Group report

Optimal therapy for post-transplant lymphoproliferative disease (PTLD) remains problematic. A phase II trial adding rituximab to a low-dose cyclophosphamide and prednisone regimen was conducted for pediatric patients with Epstein-Barr virus (EBV) (+), CD20 (+) PTLD. Fifty-five patients were enrolled...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Gross, Thomas G., Orjuela, Manuela A., Perkins, Sherrie L., Park, Julie R., Lynch, James C., Cairo, Mitchell S., Smith, Lynette M., Hayashi, Robert J.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3484187/
https://ncbi.nlm.nih.gov/pubmed/22883417
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1600-6143.2012.04206.x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky